Invasive Trophoblast Antigen (Hyperglycosylated Human Chorionic Gonadotropin) in Second-Trimester Maternal Urine as a Marker for Down Syndrome: Preliminary Results of an Observational Study on Fresh Samples

Clinical Chemistry

Volumn 50, Issue 1, 2004, Pages 182-189

  Palomaki, Glenn E ^a   Knight, George J ^a   Roberson, Marie M ^b   Cunningham, George C ^b   Lee, Jo Ellen ^c   Strom, Charles M ^c   Pandian, Raj ^c  

^a FOUNDATION FOR BLOOD RESEARCH   (United States)

^b Genetic Disease Laboratory   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; INVASIVE TROPHOBLAST ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AMNIOCENTESIS; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE MARKER; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMAN; KARYOTYPE; MATERNAL SERUM; RACE; SCREENING TEST; SECOND TRIMESTER PREGNANCY; URINALYSIS; URINE;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MATERNAL AGE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY, HIGH-RISK; TROPHOBLASTS;

EID: 1642451705     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.023986     Document Type: Article

References (31)

1. Wald NJ. Down's syndrome. In: Wald NJ, Leck I, eds. Antenatal and neonatal screening, 2nd ed. Oxford: Oxford University Press, 2000;85-115.
2. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998;5:115-9.
3. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17:821-9.
4. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
5. Cuckle HS, Canick JA, Kellner LH. Collaborative study of maternal urine β-core human chorionic gonadotrophin screening for Down syndrome. Prenat Diagn 1999;19:911-7.
6. Elliott M, Kardana A, Lustbader JW, Cole LA. Carbohydrate and peptide structure of the α- and β-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997;7:15-32.
7. Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: a new basis for gestational Down syndrome screening. Clin Chem 1999;45:2109-19.
8. Kovalevskaya G, Genbacev O, Fisher S, Caceres E, O'Connor J. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Mol Cell Endocrinol 2002;194:147-55.
9. Butler SA, Khanlian SA, Cole LA. Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices. Clin Chem 2001;47:2131-6.
10. Kovalevskaya G, Birken S, Kakuma T, Ozaki N, Sauer M, Lindheim S, et al. Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope. J Endocrinol 2002;172:497-506.
11. Pandian R, Lu J, Ossolinska-Plewnia J. Fully automated chemiluminometric assay for hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen). Clin Chem 2003;49:808-10.
12. Cole LA, Omrani A, Cermik D, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening. Prenat Diagn 1998;18:926-33.
13. Cuckle HS, Shahabi S, Schomi IK, Jones R, Cole LA. Maternal urine hyperglycosylated hCG in pregnancies with Down syndrome. Prenat Diagn 1999;19:918-20.
14. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
15. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy. The STARD Initiative. Clin Chem 2003;49:1-6.
16. Taussky HH. A microcolorimetric determination of creatinine in urine by the Jaffe reaction. J Biol Chem 1954;208:853-61.
17. Thompson SG, Barlow RD, Wald NJ, Van Vunakis H. How should urinary cotinine concentrations be adjusted for urinary creatinine concentration? Clin Chim Acta 1990;187:289-95.
18. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996;16:1115-9.
19. CDC. Vital and health statistics 2000-natality data set, series 21, no. 14 [Database on CD-ROM]. Hyattsville, MD: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 2002.
20. Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE. hCG and the free β-subunit as screening tests for Down syndrome. Prenat Diagn 1998;18:235-45.
21. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-7.
22. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
23. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11:257-68.
24. Larsen SO, Christiansen M, Norgaard-Pedersen B. Calculation of roc curves in multidimensional likelihood ratio based screening with Down's syndrome as a special case. J Med Screen 1998;5:57-62.
25. Canick JA, Kellner LH, Saller DN, Palomaki GE, Walker RP, Osanthanondh R. Second trimester levels of maternal urinary gonadotrophin peptide in Down's syndrome pregnancy. Prenat Diagn 1995;14:739-45.
26. Cuckle HS, Iles RK, Sehmi IH, Chard T, Oakey RE, Davies S, et al. Urinary multiple marker screening for Down's syndrome. Prenat Diagn 1995;15:745-51.
27. Hayashi M, Kozu H. Maternal urinary β-core fragment of hCG/ creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. Prenat Diagn 1995;15:11-6.
28. Spencer K, Aitken DA, Macri JN, Buchanan PD. Urine free β hCG and β core in pregnancies affected by Down's syndrome. Prenat Diagn 1996;16:605-13.
29. Iles RK, Butler SA, Jacoby E. Dimerization of urinary β-core/ hCFβcf: a cause of poor β-core assay performance in Down syndrome screening studies. Prenat Diagn 1999;19:790-2.
30. Cole LA, Acuna E, Isozaki T, Palomaki GE, Bahado-Singh R, Mahoney MJ. Combining β-core fragment and total oestriol measurements to test for Down syndrome pregnancies. Prenat Diagn 1997;17:1125-33.
31. Cole LA, Shahabi S, Oz UA, Rinne KM, Omrani A, Bahado-Singh RO, et al. Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG. Prenat Diagn 1999;19:351-9.